Compare ADC Therapeutics SA with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
USD 547 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.93
68.82%
-2.30
Revenue and Profits:
Net Sales:
23 Million
(Quarterly Results - Dec 2025)
Net Profit:
-6 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.03%
0%
-1.03%
6 Months
13.86%
0%
13.86%
1 Year
118.08%
0%
118.08%
2 Years
-12.47%
0%
-12.47%
3 Years
72.32%
0%
72.32%
4 Years
-72.91%
0%
-72.91%
5 Years
-86.77%
0%
-86.77%
ADC Therapeutics SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
45.22%
EBIT Growth (5y)
11.70%
EBIT to Interest (avg)
-12.16
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.07
Sales to Capital Employed (avg)
-0.41
Tax Ratio
0.62%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
75.62%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-2.30
EV to EBIT
-6.27
EV to EBITDA
-6.40
EV to Capital Employed
-46.26
EV to Sales
10.22
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 18 Schemes (8.78%)
Foreign Institutions
Held by 28 Foreign Institutions (5.41%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
23.10
16.40
40.85%
Operating Profit (PBDIT) excl Other Income
-18.30
-30.50
40.00%
Interest
13.00
13.40
-2.99%
Exceptional Items
22.00
-0.40
5,600.00%
Consolidate Net Profit
-6.40
-41.00
84.39%
Operating Profit Margin (Excl OI)
-798.50%
-1,862.30%
106.38%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 40.85% vs -12.77% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is 84.39% vs 27.56% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
81.40
70.80
14.97%
Operating Profit (PBDIT) excl Other Income
-106.50
-127.40
16.41%
Interest
51.60
50.20
2.79%
Exceptional Items
9.10
11.50
-20.87%
Consolidate Net Profit
-142.60
-157.80
9.63%
Operating Profit Margin (Excl OI)
-1,332.10%
-1,844.40%
51.23%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 14.97% vs 1.72% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 9.63% vs 34.28% in Dec 2024
About ADC Therapeutics SA 
ADC Therapeutics SA
Pharmaceuticals & Biotechnology
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
Company Coordinates 
Company Details
Biopole, route de la Corniche 3B , EPALINGES None : 1066
Registrar Details






